Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.

Shanghai and San Francisco Bay Area-based HanchorBio has already taken HCB101, an engineered SIRPα-IgG4 Fc fusion protein, into phase 2 trials for solid tumors and hematologic malignancies, including ...

Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the ...

Back in 2021, Amgen picked up the phase 3-ready candidate in a $1.9 billion acquisition of Five Prime Therapeutics. The ...

XtalPi has accrued a number of Big Pharma partners over the years, including Eli Lilly, which struck a $250 million deal in 2023 to use XtalPi’s tech to identify potential drug candidates that Lilly ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...

The latest phase 3 win is a boost for Moderna’s attempts to create a flu/COVID combination vaccine. The company withdrew a filing for FDA approval for its combo candidate last month while it waited ...

Pliant Therapeutics has terminated its idiopathic pulmonary fibrosis (IPF) program after digging into the increased rate of ...

Glaukos has claimed a series of regulatory clearances in Europe for its micro-scale surgical implants to treat patients with ...

Embattled CytoDyn and key ex-executives must face an investor lawsuit claiming the company knowingly misled shareholders ...